| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Rheumatology and
Allergy and Respiratory Diseases, Guy’s, King’s and St. Thomas School of Medicine, King’s College London, Guy’s Hospital, London, United Kingdom;
Protein Sequencing Laboratory, Imperial Cancer Research Fund, London, United Kingdom;
Department of Pediatrics, UT Medical Group Inc., Memphis, TN 38163;
¶ Department of Orthopedic Surgery, School of Medicine, Wayne State University, Hutzel Hospital, Detroit, MI 48201;
||
Infection and Immunity Research Group, King’s College London, London, United Kingdom; and
#
Institute of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
There is much circumstantial evidence implicating CD4+ T cells in the pathogenesis of RA including: the presence of activated CD45RO+CD4+ T cells within the synovial membrane (3); clinical response to therapeutic strategies that interfere with T cell function such as thoracic duct drainage and lymphoid irradiation (4); therapeutic response to cyclosporin A which interferes with IL-2 production (5); and, finally, a prompt response to i.v. infusion of anti-CD4 mAbs (6). However, a significant barrier to developing effective immunotherapies for the treatment of RA is the lack of a clearly defined autoantigen. Although several have been proposed, there is no consensus as to their relevance (7). Experimental animal studies have been instructive in defining the mechanisms of inflammation and joint destruction consequent on challenge with bacterial products (8) or joint components such as type II collagen (9) but have failed to provide direct evidence for putative autoantigens in RA.
Radical synovectomy of joints in RA results in only a temporary improvement in inflammation (10). By contrast, total knee joint arthroplasty leads to permanent cessation of inflammation in the operated knee even in the presence of ongoing inflammation elsewhere (11). We therefore propose that T cells responding to chondrocyte-specific autoantigens or those secreted in quantitatively greater amounts by chondrocytes drive rheumatoid inflammation. In an effort to characterize such autoantigens, we have adopted a proteomics approach involving Western blotting to identify possible chondrocyte Ags, determining specific sequence by tandem mass spectrometry, cloning the relevant gene, and expressing the recombinant human protein involved for subsequent immunological studies. In this study, we show that 30% of RA patients possess serum autoantibodies to BiP and 60% show synovial T cell proliferation. Mice with collagen-induced arthritis (CIA) and pristane-induced arthritis (PIA) produce anti-BiP Abs. Finally, BiP, given before immunization, inhibits the development of CIA in mice and adjuvant arthritis (AA) in rats. These results collectively suggest that BiP may indeed be an autoantigen in RA with important immunoregulatory properties for arthritis induction.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Whole cell lysates from chondrosarcoma cells (clone SW1353; HTB 94; American Type Culture Collection (ATCC), Manassas, VA) were separated by denaturing SDS-PAGE (10% or 7.5%) (12), and the proteins were transferred to nitrocellulose (13). The membranes were probed with RA, normal or disease control sera (1/100 dilution), and HRP-conjugated anti-human IgG (1/2000) (Sigma, Poole, U.K.) followed by enhanced chemiluminescence (Amersham Pharmacia Biotech, Little Chalfont, U.K.). Broad spectrum molecular mass markers were used to size the bands. The band of interest was isolated, and matrix-assisted laser desorption ionization (MALDI) time-of-flight mass spectrometry was used to identify proteins by peptide mass fingerprinting. To confirm identities, mixtures of tryptic peptides were derivatized with N-succinimidyl-2(3-pyridyl) acetate (SPA), and individual peptides were sequenced de novo using low energy collision-activated dissociation (CAD).
The electroblotted proteins were stained with Ponceau S (0.05% w/v
aqueous methanol, 0.1% acetic acid) using a rapid staining protocol
(14). The dried, stained proteins were then digested in
situ with trypsin (Boehringer Mannheim, Indianapolis, IN; modified),
and the peptides extracted with 1:1 v/v formic acid-ethanol
(15). One 0.2-µl aliquot (
5% of the total digest)
was sampled and directly analyzed by MALDI time-of-flight mass
spectrometry using a LaserMat 2000 mass spectrometer (Thermo
Bioanalysis, Hemel Hempstead, U.K.) (16). A second
0.2-µl aliquot was quantitatively esterified using 1% v/v thionyl
chloride in methanol and also analyzed by MALDI to provide acidic
residue composition (17). Native and esterified peptide
masses were then screened against the MOWSE peptide mass fingerprint
database (18). The remaining digested peptides (90% of
total digest) were then reacted with SPA to enhance 
ion abundance
and facilitate sequence analysis by tandem mass spectrometry
(19). The derivatized peptides were then sequenced by low
energy CAD using a Finnigan MAT TSQ7000 fitted with a nanoelectrospray
source (20, 21). CAD was performed using 2.5 mt argon with
collisional offset voltages between -18 V and -28 V. The product-ion
spectra were collected with Q3 scanned at 500 amu/s.
Cloning, sequencing, and expression of BIP
Human chondrocytes were isolated and cultured as described (22). Poly(A)+ mRNA (1–2 µg) was extracted from a total of 1–2 x 106 cells (Invitrogen, San Diego, CA). One microgram of mRNA was reverse transcribed into cDNA in a 20-µl reaction using 1 µl Moloney murine leukemia virus reverse transcriptase (200 U/µl), 5x first strand buffer (250 mM Tris-HCl (pH 8.3), 375 mM KCl, 15 mM MgCl2), 0.1 M DTT, oligo(dT)12–18 20 ng/µl (Life Technologies, Gaithersburg, MD), and 100 mM dNTP mix (Amersham Pharmacia Biotech).
Primer sequences for PCR were derived from the GenBank database sequence corresponding to the human gene for the Ig heavy chain binding protein, BiP (glucose-regulated protein 78), accession number X87949. The amplified cDNA consisted of most of the BiP coding region, except for the untranslated regions, signal sequences, and the stop codon. Primer sets for PCR were designed with integrated restriction sites to allow rapid subcloning of cDNA into the bacterial expression vector. The forward primers encoded an NdeI site, and the reverse primers contained an XhoI restriction site: BiP forward primer 5'-TATACATATGGAGGAGGACAAGAAGGAGGACG-3' and BiP reverse primer 5'-CCACCTCGAGTTCTGCTGTATCCTCTTCACCA-3'. After initial denaturation at 96°C for 2 min, the PCR was performed for 28 cycles using a cycling profile of 94°C for 30s, 60°C for 30s, and 72°C for 2 min, with a final extension at 72°C for 7 min. The PCR generated a single specific BiP fragment of 1890 bp. The 1890-bp PCR fragment was digested with both NdeI and XhoI. The purified fragment was ligated into the NdeI/XhoI predigested bacterial expression vector pET30a (Novagen, Madison, WI). The ligated plasmids were transformed into competent Escherichia coli XL1-Blue (Stratagene, La Jolla, CA) and screened by colony-PCR using BiP-specific primers. Positive transformants carrying the required recombinant plasmids were purified and transformed into competent E. coli expression strain BL21-(DE3) (Invitrogen).
Extensive DNA sequencing of the 1890-bp pET30::BiP subclone was performed using synthetic oligonucleotide primers spanning the entire length of the BiP subclone. All DNA sequencing was performed on an Applied Biosystems ABI 377 automated DNA sequencer using the dRhodamine dye terminator kit (Perkin-Elmer-Applied Biosystems, Foster City, CA).
Expression and purification of bacterial recombinant proteins. E. coli expression strain BL21-(DE3) containing the recombinant pET30a-BiP plasmid was grown at 37°C in Luria-Bertani (LB) medium containing kanamycin (50 µg/ml). When the cells had reached an OD600 of 0.6 U, isopropyl-D-thiogalactopyranoside (1 mM) was added to the medium to induce expression of the recombinant protein. For maximal expression of the recombinant protein, the culture was incubated for a further 4 h at 37°C. Cells were pelleted by centrifugation and stored at -70°C. For purification of the recombinant bacterial proteins, the bacterial pellets were lysed in binding buffer (20 mM Na2HPO4, 500 mM NaCl, 5 mM imidazole, 1 mM PMSF, 1 mg/ml lysozyme, 5 µg/ml DNase, 0.1% Triton X-100, pH 7.4). The lysate was cleared by centrifugation and passed over a binding buffer-equilibrated chelating Hi-trap affinity column (Pharmacia). The nonspecifically bound protein was washed from the column under stringent conditions using a series of three wash buffers. The primary wash was performed using 100 ml binding buffer. This was followed by a high stringency low pH wash (20 mM Na2HPO4, 500 mM NaCl, 0.1% Triton X-100, pH 5.5) and an additional high stringency wash using 100 ml 20 mM Na2HPO4, 500 mM NaCl, 0.1% Triton X-100, 50 mM imidazole, pH 7.4. The histidine-tagged recombinant proteins were eluted from the column by stripping with 50 mM EDTA. Eluted proteins were dialyzed against PBS to remove EDTA and nickel contaminants. The purified protein was concentrated and washed in sterile PBS using a 50,000 m.w. cutoff concentrator column (Millipore, Bedford, MA). The total amount of protein was determined by spectrophotometry using BSA as a standard with the bicinchoninic acid assay (Sigma; according to manufacturer’s instructions). The concentrated BiP recombinant protein was dissolved in PBS and stored at -70°C.
Confirmation of BiP as Ag. Western blots of chondrosarcoma lysate and recombinant human BiP (rhuBiP) were prepared as previously described (12, 13) and probed with RA sera (1/100 dilution) either before or after absorbing the sera with rhuBiP for 1 h at 20°C.
Immunological studies in patients with RA
Demographic details of RA patients and controls.
The details are given in Table I
.
Eighty-three percent of patients with RA, diagnosed by the American
College of Rheumatology criteria (23) were rheumatoid
factor positive. The range of disease duration was 2–25 years. No
patient had disease of <2 years duration. Disease controls consisted
of patients with ankylosing spondylitis or psoriatic arthritis. RA
patients were receiving a mixture of nonsteroidal antiinflammatory
drugs or disease modifying drugs with or without prednisolone (
7.5 mg
daily). Control patients with other inflammatory joint diseases (OIJD)
were on a similar regimen. The normal healthy controls, whose sera were
used for the Western blotting, consisted of 8 women and 3 men whose age
was 49.3 ± 9.8 and 52.6 ± 12.7 years (mean ± SD),
respectively.
|
production by peripheral blood (PB) and synovial fluid (SF)
mononuclear cells. Mononuclear cells were separated from heparinized PB
or SF by density centrifugation using Lymphoprep (Nycomed-Amersham,
Little Chalfont, U.K.). Preliminary experiments had shown that 20
µg/ml was the optimum concentration of BiP to use in proliferation
studies (data not shown). As control stimulants, proliferation assays
were conducted using tuberculin protein purified derivative (Central
Veterinary Laboratories, Weybridge, U.K.) at optimal dose (10 µg/ml),
and PWM (Sigma; 2 µg/ml). Cells were cultured for 6 days at 37°C in
5% CO2 and pulsed with 0.2 µCi
[3H]thymidine/well 24 h before harvesting.
Proliferation was expressed as a stimulation index (SI): proliferation
in the presence of stimulant/proliferation in the presence of medium
alone. Tissue typing of patients and controls. Tissue typing for HLA-DR was conducted in the Tissue Typing Department, Guy’s Hospital, using PCR-sequence-specific primers as described (24).
Immunological studies in experimental arthritis
Ab response to BiP in experimental arthritis. CIA and PIA were induced in DBA/1 mice according to previously described protocols (25, 26). Mice were bled before induction of arthritis (15 animals), at the onset of CIA (16 animals), and at the onset of PIA (14 animals). The Ab in mouse sera against BiP was determined using ELISA with recombinant BiP and expressed as mean ± SEM OD450 U and analyzed by two-tailed t test for unpaired samples. A similar procedure was used to determine Abs to type II collagen (27).
Induction of arthritis by injection of BiP. Male WA/KIR/kcl rats (n = 7) bred at King’s College London (KCL), 10–13 wk old, were injected intradermally over the scapulae with 500 µg BiP in IFA (Sigma), and the same injection was repeated i.v. 26 days later. Male B10.RIII mice (Harlan Orlac, 8–10 wk old, n = 8), male DBA/1 mice (Harlan Olac, 8–9 wk old, n = 8) and male BALB/c mice (bred at KCL, 10 wk of age, n = 5) were injected intradermally over the scapulae with 100 µg BiP in CFA (Difco, Detroit, MI) and repeated by same route on day 26. Mice were observed for 90 days and rats for 42 days for signs of arthritis. HLA-DRB1*0401 (28)- and HLA-DRB1*0101 (29)-transgenic mice were immunized with 100 µg BiP emulsified in CFA s.c. at the base of the tail and a second dose of 100 µg emulsified in IFA 3 wk later. Arthritis was scored 8 wk later. Where indicated, arthritis was scored as the number of animals and the number of joints per animal with clinical arthritis and the histological appearance of the joints as previously described (25, 26, 28, 29).
Modulation of adjuvant arthritis with BiP.
Heat-killed Mycobacterium tuberculosis (strain H37Ra) was
obtained from Difco. Dimethyl dioctadecyl ammonium bromide (DDA;
Eastman Kodak, Rochester, NY), used as adjuvant was prepared as a
20-mg/ml suspension in PBS and sonicated/heated to produce a gel, which
was mixed 1:1 with Ag solution before immunization. Male Lewis rats
(n = 5), obtained from the University of Limburg
(Maastricht, the Netherlands) 6–8 wk old, were immunized with 50 µg
BiP in 50 µl PBS/DDA in each hind footpad (i.e., 100 µg/rat).
Control animals (n = 5) received only the PBS/DDA
mixture. Thirteen days later, AA was induced by a single intradermal
injection of 0.5 mg M. tuberculosis in 100 µl IFA in the
base of the tail. Rats were examined daily for clinical signs of
arthritis in a blinded setup. Severity of arthritis was assessed by
scoring each paw from 0 to 4 based on the degree of swelling, erythema,
and deformity of the joints (30). Thus, the maximum score
per rat was 16. The weight of individual rats was scored every other
day. Differences between experimental groups were evaluated for the
maximum arthritis score observed for each rat by means of the
two-tailed Mann-Whitney U test. Differences were considered
significant at p 0.05. Vehicle was used as the
control for BiP in these experiments as the administration of other
highly conserved nonself proteins did not protect against arthritis
development (31).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Western blotting was used to detect differences between RA and
control sera for the identification of chondrocyte Ags. When RA and
control sera were blotted against chondrosarcoma extracts, 30% RA sera
(n = 54) reacted with a 70–80 kDa protein compared
with 10% of control sera (n = 11) (Fig. 1A). No correction has been
made for the IgG concentration of individual sera. Peptide mass
fingerprint analysis and de novo sequencing of tryptic peptides by low
energy CAD identified one of the proteins in the 70- to 80-kDa region
as the 78-kDa glucose-regulated protein, a human chaperone also known
as Ig heavy chain binding protein (BiP). DNA sequence analysis of BiP
from articular chondrocyte cDNA showed a number of deviations from the
original published sequence (accession number X87949). These
differences were confirmed by sequencing of BiP cDNAs isolated from
PBMC of six individuals. A total of six single nucleotide substitutions
and a codon insertion result in three amino acid substitutions and an
arginine insertion at position 834–836 of BiP (accession number
AF188611).
|
B
shows Western blots of both chondrosarcoma lysate and rhuBiP. In both
cases, the RA sera showed a band, indicating Ab to the protein on the
nitrocellulose; however, incubation of RA sera with rhuBiP completely
neutralized the Ab response. Immunological studies in RA
T cell-proliferative responses were determined for mononuclear
cell preparations from paired PB and SF samples obtained from 23
patients with RA and from 12 disease controls. Twelve of 23 (52%)
patients with RA and only 2 of 12 (17%) of disease controls showed
increased synovial proliferation to BiP (Fig. 2A). The proliferative
response to BiP of RA synovial T cells was significantly higher than
that of the paired PB (SI, mean ± SEM: SF 3.5 ± 0.7; PB
1.6 ± 0.2; p < 0.01, Wilcoxon paired test). A
significant difference was also seen between SF responses to BiP
between RA patients and disease controls (SI: RA 3.5 ± 0.7; OIJD
1.4 ± 0.2; p = 0.03, Mann-Whitney U
test). There was no significant difference between the proliferation of
PB and SF cultures for the inflammatory disease controls
(p = not significant, Wilcoxon paired test).
The increased proliferation by RA SF T cells could have been due to
contaminating E. coli proteins. -Galactosidase was
prepared in the same expression system as the BiP but did not induce RA
SF T cell proliferation (Fig. 2B). Another possible
contaminant could be endotoxin, but six separate RA SF experiments did
not show any T cell proliferation at 20 ng/ml endotoxin (SI 1.4 ±
0.2, mean ± SEM), whereas BiP showed the expected proliferation
(SI 3.5 ± 0.7).
|
Immunological studies in experimental arthritis
Induction of experimental arthritis with BiP. BiP did not induce arthritis in DBA/1-, BALB/c-, B10.RIII-, HLA-DR1+/+-, or HLA-DR4+/--transgenic mice or WA/KIR/kcl rats (data not shown).
Immune response to BiP in experimental arthritis.
We next investigated whether DBA/1 mice made Abs against BiP during the
course of CIA or PIA (Fig. 3). DBA/1 mice
developed serum anti-BiP Abs at the onset of collagen arthritis
(0.189 ± 0.042) and PIA (0.504 ± 0.074) when compared with
prebleed sera (0.070 ± 0.019; p < 0.02 vs CIA
and p < 0.00001 vs PIA, respectively). The
concentration of these Abs was significantly higher in PIA mice than in
CIA mice (p < 0.007).
|
). Whereas 5 of 6 animals
had 11 of 24 limbs that were involved with arthritis at 8 wk when
pretreated with saline, only 1 of 10 animals had 1 of 40 limbs involved
with arthritis in the group previously given i.v. BiP. These
differences are highly significant (p 0.008
and p 0.0001, respectively). Table II also shows
that there was a significant reduction in anti-collagen Abs in the
BiP-pretreated animals to one-third the level in the controls. The
control mice, pretreated with PBS, had twice as much IgG2 as IgG1
anti-collagen Abs, whereas mice pretreated with BiP had almost
equivalent amounts of IgG1 and IgG2 anti-collagen Abs. (Table III). The histology of the joints of
these animals (Fig. 4) confirmed the
clinical findings in that there was no synovitis in the joints of
BiP-pretreated mice.
|
|
|
, BiP not only delayed the onset of
arthritis and but also suppressed the severity of the disease. At the
maximum of the disease in the control animals (days 15–21), a
significant suppression was observed in the BiP-treated animals
(p < 0.05). Weight curves (a sensitive
objective measure of physical well-being) of rats immunized with BiP
were also significantly distinct from the weight curves in
PBS-pretreated rats (data not shown)
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Induction of BiP expression, which is primarily due to transcriptional activation (36), may be brought about by a number of cellular stress mechanisms including ischemia and/or reperfusion injury (37), glucose starvation (36), failure of glycosylation or malfolding of proteins (38, 39), heat stress (38), cytokines (40), oxidative stress, and depletion of intracellular Ca2+ stores. There is evidence that up-regulation of BiP may be involved in the immune response to tumors or during allograft rejection. Cells staining positively for BiP are found among the inflammatory cell infiltrate of rejecting rat cardiac allografts (41) and T cells from the allograft proliferate when cultured with BiP in the presence of autologous APCs (41). These observations are of relevance to our findings in RA as they confirm that T cell autoimmunity can arise to BiP. The presence of anti-BiP Abs in the sera of 4 of 21 patients with delayed onset reactions to sulfonamide antibiotics (42) further suggests that an immune response to BiP may be stimulated under appropriate conditions. Because of the prominent role of microbial HSP in the pathogenesis and immunotherapy of experimental forms of arthritis, much effort has been expended in defining their role in the pathogenesis of RA. Human HSP60 (43) and human homologues of the bacterial chaperone DnaJ (44) are expressed in the rheumatoid synovial membrane. Although some investigators have provided evidence for preferential T cell responses by RA patients to mycobacterial hsp65 (45), the majority have been unable to do so (46, 47).
Earlier studies have shown that immunization with mycobacterial hsp70 reduces the severity of both AA and avridine arthritis, a nonmicrobial agent-induced experimental arthritis. Disease suppression was found to be related to the induction of regulatory T cells cross-reactive with self-hsp70 that triggered the production of IL-10 (31). This phenomenon was specific for hsp70, because other highly conserved nonself proteins did not protect and did not induce IL-10 (31). In the present study, we show for the first time that a similar suppression of arthritis can be induced with BiP, a member of the hsp70 family, when BiP is given i.v. before the induction of CIA in DBA/1 mice or AA in Lewis rats. In the CIA model, mice pretreated with i.v. PBS had twice as much IgG2 and IgG1 anti-collagen Abs as did the mice pretreated with BiP, in which they were almost equal. This suggests that BiP may have immunomodulatory properties because it appears to be able to significantly suppress a Th1 Ab. This suggests that regulatory, self-hsp70-reactive T cells can be activated and expanded not only by immunization with M. tuberculosis hsp70 but also with homologous self-hsp70. As it has been demonstrated that the synthesis of hsp, such as hsp70, is up-regulated in arthritic joints (48), it is likely that MHC presentation of self-hsp peptides is also enhanced in arthritic joints. Therefore, migrating BiP-specific T cells may encounter their Ag in the joints (or the respective draining lymph node) on "stressed" APC or MHC II-positive activated T cells to exert their predicted regulatory activity. The immunomodulatory properties of BiP-activated T cells in these experimental systems are presently under investigation.
The observations described in this work are the first, to our knowledge, that implicate an endogenous chaperone in the pathogenesis of RA and the immunotherapy of experimental arthritis. BiP is, therefore, a strong candidate for the immunotherapy of RA.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 V.M.C., M.D.B.-S., and M.S.F. contributed equally to the work.
3 Address correspondence and reprint requests to Dr. Gabriel S. Panayi, Arthritis Research Campaign Professor of Rheumatology, Guy’s Hospital, London, SE1 9RT, U.K.
4 Abbreviations used in this paper: RA, rheumatoid arthritis; CIA, collagen-induced arthritis; PIA, pristane-induced arthritis; AA, adjuvant arthritis; OIJD, other inflammatory joint diseases; rhuBiP, recombinant human BiP; SPA, N-succinimidyl-2(3-pyridyl) acetate; CAD, collision-activated dissociation; MALDI, matrix-assisted laser desorption ionization; LB, Luria-Bertani; PB, peripheral blood; SF, synovial fluid; DDA, dimethyl dioctadecyl ammonium bromide; SI, stimulation index; hsp, heat shock protein; KCL, King’s College London.
Received for publication June 1, 2000. Accepted for publication November 8, 2000.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  A. von Delwig, D. M Altmann, F. G Charlton, N. McKie, J. D Isaacs, R. Holmdahl, and J. H Robinson T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1*0101 transgenic mice Ann Rheum Dis, May 1, 2007; 66(5): 599 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Szodoray, P. Alex, M. B. Frank, M. Turner, S. Turner, N. Knowlton, C. Cadwell, I. Dozmorov, Y. Tang, P. C. Wilson, et al. A genome-scale assessment of peripheral blood B-cell molecular homeostasis in patients with rheumatoid arthritis Rheumatology, December 1, 2006; 45(12): 1466 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Dzhambazov, K. S. Nandakumar, J. Kihlberg, L. Fugger, R. Holmdahl, and M. Vestberg Therapeutic Vaccination of Active Arthritis with a Glycosylated Collagen Type II Peptide in Complex with MHC Class II Molecules J. Immunol., February 1, 2006; 176(3): 1525 - 1533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Quintana and I. R. Cohen Heat Shock Proteins as Endogenous Adjuvants in Sterile and Septic Inflammation J. Immunol., September 1, 2005; 175(5): 2777 - 2782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Bodman-Smith, M. F. Fife, H. Wythe, V. M. Corrigal, G. S. Panayi, L. R. Wedderburn, and P. Woo Anti-BiP antibody levels in juvenile idiopathic arthritis (JIA) Rheumatology, October 1, 2004; 43(10): 1305 - 1306. [Full Text] [PDF]
|
|
|
|
|
|
M. D. Bodman-Smith, V. M. Corrigall, E. Berglin, H. R. Cornell, A. G. Tzioufas, C. P. Mavragani, C. Chan, S. Rantapaa-Dahlqvist, and G. S. Panayi Antibody response to the human stress protein BiP in rheumatoid arthritis Rheumatology, October 1, 2004; 43(10): 1283 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. M. van Bilsen, J. P. A. Wagenaar-Hilbers, M. C. J. T. Grosfeld-Stulemeijer, M. J. F. van der Cammen, M. E. A. van Dijk, W. van Eden, and M. H. M. Wauben Matrix Metalloproteinases as Targets for the Immune System during Experimental Arthritis J. Immunol., April 15, 2004; 172(8): 5063 - 5068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D M Lee and P H Schur Clinical utility of the anti-CCP assay in patients with rheumatic diseases Ann Rheum Dis, September 1, 2003; 62(9): 870 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. B. McInnes, B. P. Leung, M. Harnett, J. A. Gracie, F. Y. Liew, and W. Harnett A Novel Therapeutic Approach Targeting Articular Inflammation Using the Filarial Nematode-Derived Phosphorylcholine-Containing Glycoprotein ES-62 J. Immunol., August 15, 2003; 171(4): 2127 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Bodman-Smith, V. M. Corrigall, D. M. Kemeny, and G. S. Panayi BiP, a putative autoantigen in rheumatoid arthritis, stimulates IL-10-producing CD8-positive T cells from normal individuals Rheumatology, May 1, 2003; 42(5): 637 - 644. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
2.5 was considered significant. A,
Proliferation to 20 µg/ml BiP. B, Proliferation
to 20 µg/ml 
) and to 20 µg/ml BiP (•) by
four RA SF mononuclear cell preparations. + indicates mean SI ±
SD.
